Netanya S Utay
Overview
Explore the profile of Netanya S Utay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reimer-McAtee M, Serpa J, McAtee C, Ortega E, Somasunderam A, Arduino R, et al.
medRxiv
. 2025 Feb;
PMID: 39974003
Systemic inflammation is a major driver of comorbidities in people with HIV (PWH). Increased levels of biomarkers of enterocyte turnover, microbial translocation, and systemic inflammation have been shown to predict...
2.
Lake J, Hyatt A, Feng H, Miao H, Somasunderam A, Utay N, et al.
Transgend Health
. 2024 Oct;
9(5):413-420.
PMID: 39449788
Purpose: Non-alcoholic fatty liver disease (NAFLD) prevalence and severity may be higher in people with human immunodeficiency virus (HIV) than the general population, and vary with sex and age. We...
3.
Utay N, Guerri-Fernandez R, Gharakhanian S, Asmuth D, Contreras M, Kunkler C, et al.
J Med Virol
. 2024 Oct;
96(10):e70005.
PMID: 39390688
Effective treatment to prevent hospitalization and death in people with COVID-19 exists, but people still need interventions that alleviate symptoms without drug interactions. Oral serum-derived bovine immunoglobulins (SBI) may reduce...
4.
Bulnes R, Utay N
Curr Opin HIV AIDS
. 2024 Jun;
19(5):268-275.
PMID: 38874442
Purpose Of Review: Dysbiosis may be a key driver of systemic inflammation, which increases the risk of non-AIDS events in people living with HIV (PLWH). Modulation of the microbiome to...
5.
Huang D, Ajmera V, Tomaszewski C, LaFree A, Bettencourt R, Thompson W, et al.
Adv Ther
. 2023 Aug;
40(11):4805-4816.
PMID: 37615850
Introduction: Retrospective studies report that angiotensin-converting enzyme inhibitors (ACEIs) may reduce the severity of COVID-19, but prospective data on de novo treatment with ACEIs are limited. The RAMIC trial was...
6.
Lake J, Taron J, Ribaudo H, Leon-Cruz J, Utay N, Swaminathan S, et al.
AIDS
. 2023 Jul;
37(14):2149-2159.
PMID: 37503623
Background: Hepatic steatosis, including nonalcoholic fatty liver disease (NAFLD), is common among people with HIV (PWH). We present baseline steatosis prevalence and cardiometabolic characteristics among REPRIEVE substudy participants. Methods: REPRIEVE...
7.
DuPont H, Suescun J, Jiang Z, Brown E, Essigmann H, Alexander A, et al.
Front Neurol
. 2023 Mar;
14:1104759.
PMID: 36937520
Background And Purpose: The intestinal microbiome plays a primary role in the pathogenesis of neurodegenerative disorders and may provide an opportunity for disease modification. We performed a pilot clinical study...
8.
Govind A, Lazarte S, Kitchell E, Chow J, Estelle C, Fixsen E, et al.
Clin Infect Dis
. 2023 Jan;
76(10):1843-1846.
PMID: 36718662
In the current mpox outbreak, infections are usually self-limited. We describe 3 patients with uncontrolled HIV and mpox infections lasting months, causing debilitating lesions, complications, and death, despite initiating anti-mpox...
9.
Chew K, Wu K, Tassiopoulos K, Palella F, Naggie S, Utay N, et al.
Clin Infect Dis
. 2022 Sep;
76(3):e571-e579.
PMID: 36049028
Background: We sought to characterize in people with human immunodeficiency virus (PWH) the potential etiologies of elevated alanine aminotransferase (ALT) levels, which are common and often unexplained. Methods: Participants from...
10.
Presti R, Yeh E, Williams B, Landay A, Jacobson J, Wilson C, et al.
Open Forum Infect Dis
. 2021 Dec;
8(12):ofab550.
PMID: 34888397
Background: A5350, a phase II, randomized, double-blind study, evaluated the safety and tolerability of the probiotic Visbiome Extra Strength (ES) over 24 weeks and measured effects on inflammation and intestinal...